+ T cell differentiation. We used Listeria monocytogenes infection to characterize the function of IRF4 in T H1 responses. IRF4 −/− mice generated only marginal numbers of listeria-specific T H1 cells. After transfer into infected mice, IRF4
. In B cells, IRF4 controls the germinal center reaction and high IRF4 expression is a prerequisite for plasma cell formation. As a consequence, antibodies are almost completely absent in IRF4-deficient mice 8, 9 . Naive peripheral T cells express only low levels of IRF4. Upon T cell receptor stimulation, IRF4 is rapidly expressed and subsequently controls differentiation processes of these cells 1, 8, 10, 11 . Deficiency of IRF4 in CD4 + T cells results in a complete block in the formation of T H2 , T H9 , T H17 and follicular T H (T FH ) cells [12] [13] [14] [15] [16] [17] [18] [19] [20] . Although IRF4-deficiency allows the generation of Foxp3 + T reg cells, these cells are impaired in their suppressive functions 21, 22 . IRF4 also controls peripheral CD8 + T cells differentiation. We and others could demonstrate that following antigen recognition, IRF4-deficient CD8 + T cells start to proliferate and to express effector molecules such as IFN-γ and granzyme B. However, IRF4-deficent cells cannot sustain proliferation and fail to upregulate effector molecules to the level observed in wild type CD8 + effector T cells. In line with these results, IRF4-deficient CD8 + T cells express reduced levels of transcription factors associated with CD8 + effector T cell formation including T-bet, BLIMP1 and ID2 8, 11, [23] [24] [25] [26] [27] . In contrast to other IRF family members, IRF4 binds interferon stimulated response elements (ISRE) with low affinity. However, in cooperation with transcription factors of the Ets or AP-1 families, IRF4 is able to strongly bind to Ets-IRF composite elements (EICE) or AP-1-IRF composite elements (AICE), respectively 9, 28 . Cooperative binding with the Ets proteins PU.1 and SpiB to EICE has been demonstrated for B cells and myeloid cells. However, both transcription factors are usually not expressed in T cells, indicating that interaction of IRF4 with EICE does not commonly occur in T cells 29, 30 . In contrast, T cells express the AP-1 proteins BATF, JunB, JunD and c-Jun, and cooperative binding of IRF4 with heterodimers of BATF and Jun family members was demonstrated for T H17 cells and CD8
+ T cells [29] [30] [31] . Using mRNA expression studies and chromatin immune precipitation (ChIP), target genes for IRF4 have been determined for T H17 and CD8 + T cells. These targets include a large number of genes involved in T cell activation and differentiation 25, [30] [31] [32] . Interestingly, IRF4 and BATF frequently bind to regulatory DNA regions outside the promotors. Therefore, it was proposed that IRF4 and BATF might act as pioneering factors that promote and sustain chromatin remodeling and enhance accessibility of genes for other transcription factors, including lineage-specific factors such as T-bet or RORγ t 25, 29, 31, 32 . In CD8 + T cells, IRF4 controls expression of transcription factors involved in effector cell differentiation including Tbx21 (encoding T-bet), Prdm1 (encoding BLIMP1), Runx3 and Tcf7 (encoding TCF-1), as well as effector proteins such as cytokines and cytolytic proteins 11, 25, 26 . IRF4 is also involved in the metabolic changes of CD8 + T cells following activation. Naive T cells show basal levels of glucose and amino acid uptake and mainly use oxidative phosphorylation and fatty acid oxidation for energy production. T cell activation causes enhanced nutrient uptake as well as increased aerobic glycolysis and glutaminolysis. These changes in the metabolic profile are necessary to provide energy and substrates for de novo synthesis of proteins, nucleic acids and lipids required for proliferation and effector protein production [33] [34] [35] [36] . Metabolic changes are controlled by different transcription factors including HIF1α , FOXO1 and FOXO3. IRF4 modulates the expression of these factors but also directly enhances expression of several proteins involved in nutrient uptake and glycolysis 25, 33 . Impaired adaptation to metabolic demands can explain the failure of IRF4-deficient CD8 + T cells to sustain proliferation and to develop into mature effector cells 25, 33 . IRF4 expression levels correlate with the strength of the TCR signal, thereby IRF4 links TCR affinity with the extent of metabolic changes following CD8
+ T cell activation. It has been proposed that during immune responses this mechanism promotes the preferential expansion of high affinity CD8 + T cell populations 25, 27, 33 .
In contrast to its function in CD8
+ T cells and CD4 + T H cell subsets described above, the role IRF4 in T H1 cell development is less clear. T H1 differentiation of IRF4 −/− CD4 + T cells has been analyzed in vitro and in vivo using the Leishmania major infection model, with inconsistent results [12] [13] [14] 17 . Although all studies provided evidence for T H1 differentiation of IRF4 −/− CD4 + T cells, the efficacy of this process ranged from marginal to close to that observed in WT cells.
Here, we use the Listeria monocytogenes infection model to analyze the role of IRF4 in T H1 cell differentiation and function. We demonstrate that IRF4 is crucial for the generation of a T H1 response. IRF4
−/− CD4 + T cells showed impaired T H1 differentiation and only limited proliferation after in vitro and in vivo activation. Compared to control cells, activated IRF4
−/− CD4 + T cells exhibited impaired aerobic glycolysis and oxidative phosphorylation and this restricted metabolism could be responsible for the poor response of these cells.
Results

IRF4-deficient mice fail to mount a T H1 response to Listeria monocytogenes. Wild type (WT) and IRF4
−/− mice were infected with LmOVA, a L. monocytogenes strain recombinant for ovalbumin 37 , and after 8 days the CD4 + T H1 response was analyzed. In WT mice, about half of the CD4 + T cells presented an activated CD44 + CD62L − phenotype ( Figure S1 ). IRF4 −/− mice also accumulated CD62L − CD4 + T cells, however, these cells failed to up-regulate CD44. CD4 + T cells from infected mice were stimulated with the immunodominant listeriolysin O peptide LLO 189-201 and the expression of CD40L (CD154) 38 , IFN-γ and TNF-α was determined by intracellular staining (Fig. 1 and Figures S2 and S3) . Following LLO 189-201 stimulation, approx. 2% of CD4 + T cells from infected WT mice responded with up-regulation of CD40L and more than half of these cells co-expressed high levels of IFN-γ and TNF-α , a hallmark of T H1 cells. LLO 189-201 -specific CD4 + T cells were significantly reduced in IRF4 −/− mice, as indicated by the reduced frequencies of CD40L + cells. Only a small fraction of these CD40L
+ cells co-expressed IFN-γ and TNF-α and particularly IFN-γ + TNF-α + cells were substantially reduced in IRF4
−/− mice. In addition, cytokine-positive IRF4 −/− CD4 + T cells displayed diminished staining intensity for IFN-γ and TNF-α , indicating that cells produced only low amounts of the cytokines (Fig. 1a,b) .
IRF4
− + T cells had outnumbered the IRF4 −/− CD4 + T cells by a factor of 4 (Fig. 2a,b) . WT CD4 + T cells had uniformly acquired a CD44 + CD62L − CD127 − phenotype (Fig. 2c and Figure S4a) Fig. 2d and Figure  S4b ). In contrast, the IRF4 −/− CD4 + T cells showed reduced up-regulation of CD40L and only a small population was IFN-γ
Finally, expression of the transcription factor T-bet was determined by intracellular staining (Fig. 2e,f (Fig. 3a,b) . Accordingly, transferred IRF4
−/− OT-II cells remained to a larger extend CFSE-positive and this cell population failed to expand in infected or peptide-treated animals ( Fig. 3c-e) . In recipients infected with LmOVA, transferred WT OT-II cells expressed enhanced levels of IRF4 ( Figure S5a 
−/− CD4 + T cells show reduced T H1 differentiation in vitro. To test whether absence of IRF4 prevents T H1 differentiation, WT and IRF4 −/− CD4 + T cells were mixed to obtain a ratio of 1:1, and polyclonally stimulated under T H1 cell inducing conditions. On day 4, cells were restimulated and tested for the expression of IFN-γ . Whereas 80% of WT CD4
+ T cells expressed IFN-γ , only about 50% of IRF4 −/− CD4 + T cells were IFN-γ + (Fig. 5a ), and in these cells the mean IFN-γ expression level was lower than in the respective WT cells. In accordance with the impaired IFN-γ production, we could also observe diminished up-regulation of T-bet in IRF4
−/− CD4 + T cells (Fig. 5b) . Thus, IRF4-deficiency impaired but did not generally prevent T H1 differentiation. Activated CD4
+ T cells were also analyzed by quantitative PCR for the expression of Runx3 and Prdm1, coding for two transcription factors involved in T-cell differentiation and representing targets of IRF4 in CD8 + T cells 25, 26 . In contrast to CD8
+ T cells, we observed similar induction for both Runx3 and Prdm1 in WT and IRF4 −/− CD4 + T cells ( Figure S6a 
CD4
+ T cells showed initial reduction of CFSE staining intensity. After 2-3 days, decrease of CFSE staining was halted in IRF4 −/− CD4 + T cells. In contrast, WT CD4 + T cells continued to lose staining intensity. A similar response was observed when WT and IRF4
−/− CD4 + T cells were activated in individual cultures ( Figure S7c ). In accordance with these observations, activated IRF4 −/− CD4 + T cells showed enhanced mRNA expression for the cyclin-dependent kinase inhibitor Cdkn2a, which has been identified as IRF4 target in CD8 + T cells 26 ( Fig. 5e ).
In vitro activated CD4
+ T cells were also analyzed for induction of apoptosis ( Figure S8a ). CD4 + T cells were stimulated and the proportion apoptotic was determined by measuring binding of the caspase substrate FLICA and uptake of propidium iodide (PI) −/− CD4 + T cell population was mainly due to reduced proliferation and only to a minor degree to enhanced apoptosis.
IRF4
−/− CD4 + T cells are impaired in cellular metabolism. For CD8
+ T cells, it has been shown that IRF4 controls expression of proteins involved in central metabolic pathways such as glucose uptake, glycolysis and oxidative phosphorylation and thereby promotes changes in cell metabolism necessary for T cell proliferation and effector functions 25 . Recently it was also demonstrated that T H1 differentiation of CD4 + T cells is associated with similar metabolic changes 39 . To test whether IRF4 controls the metabolism of T H1 cells, WT and IRF4
−/− CD4 + T cells were activated and uptake of the fluorescent glucose analog 2-NBDG was measured by flow cytometry (Fig. 6a) . Activation caused enhanced 2-NBDG uptake in WT and IRF4
−/− CD4 + T cells, but uptake was reduced in IRF4 −/− CD4 + T cells. The bioenergetics profile of IRF4 −/− T H1 cells was then tested with extracellular flux assays (Fig. 6b,c) . Following activation, basal oxygen consumption rates (OCR) were slightly lower in IRF4 −/− than in WT CD4
+ T cells (Fig. 6b) . OCR was similar in both cell populations following treatment with the ATP synthase inhibitor oligomycin, however, IRF4
−/− CD4 + T cells showed impaired OCR increase in response to −/− OT-II cells were smaller and expressed reduced levels of the transferrin receptor CD71 than WT OT-II cells (Fig. 6d) . These IRF4 −/− OT-II cells also showed diminished ability to take up 2-NBDG. In line with these results and similar to CD8 + T cells 25 , we observed reduced mRNA expression for the glucose transporter GLUT3 (Slc2a3) and the central glycolysis enzyme hexokinase 2 (Hk2) in in vitro activated IRF4 −/− CD4 + T cells (Fig. 6e) . Thus, IRF4 apparently controls metabolism in CD4 + T cells by regulating the expression of nutrient transporters and glycolysis enzymes. Interestingly and in contrast to IRF4 −/− CD8 + T cells 25 , we did not observe altered mRNA expression for the transcription factor HIF1α , a central regulator of cellular metabolism.
In conclusion, our results indicate that IRF4 is crucial for the regulation of metabolism in T H1 cells which results in a failure to mount T H1 responses.
Discussion
Our study demonstrates that IRF4 is essential for effective formation of T H1 responses. Following
L. monocytogenes-infection, listeria-specific IRF4
−/− CD4 + T cells showed impaired T H1 differentiation and failed to expand to the level observed for WT CD4 + T cells. Published analyses of the role of IRF4 in T H1 differentiation revealed inconsistent results [12] [13] [14] . In vitro, IRF4-deficient CD4 + T cells showed either normal T H1 differentiation 13, 14 or were significantly impaired 14 . Following L. major infection, studies described normal 13 or severely diminished IFN-γ production 14 when cells from lesion draining lymph nodes were stimulated with leishmania-antigen. In our study, we observed limited accumulation of specific IRF4
−/− CD4 + T cells in response to L. monocytogenes infection or peptide immunization. Remaining specific IRF4
−/− CD4 + T cells were impaired −/− CD4 T cells could also explain the inconsistent published results on IRF4 and T H1 differentiation [12] [13] [14] .
Impaired expansion of the IRF4
+ CD4 + T cell population could be due to limited proliferation or a failure of survival and enhanced apoptosis. In contrast to a previous study 40 , we did not observe substantially enhanced apoptosis of IRF4 −/− CD4 + T cells when compared to WT cells in in vitro assays. In this study, apoptosis was determined after re-stimulation of highly activated CD4 + T cells, which might explain the different outcome when compared to our study, where apoptosis was measured following primary stimulation of naive CD4 + T cells. The small difference in apoptosis in our study was also consistent with the similar induction of the anti-apoptotic BCL2 and pro-apoptotic BIM in WT and IRF4
−/− CD4 + T cells. Our results rather indicate that IRF4 −/− CD4 + T cells have a defect in differentiation and proliferation. We observed diminished blast formation, reduced expression of activation markers and limited proliferation, as evident by less pronounced loss of CFSE staining. The Cdkn2a gene was identified as direct IRF4 target in CD8 + T cells and it was postulated that IRF4 acts as repressor of Cdkn2a expression and thereby allows proliferation of CD8 + T cells 26 . A similar mechanism could also be active in CD4
+ T cells and restrict the proliferation of IRF4 −/− CD4 + T cells. In CD8 + T cells, IRF4 controls the adaption of the cellular metabolism to the requirements of proliferation and production of effector proteins following activation 25, 33 . Activation of CD4
+ T H cells also causes profound changes of metabolic pathways including up-regulation of aerobic glycolysis [34] [35] [36] 39 . Our results reveal that IRF4 is important for these changes in CD4 + T cells. Activated IRF4 −/− CD4 + T cells showed diminished surface expression of the transferrin receptor as well as reduced mRNA expression of the glucose transporter GLUT3 and impaired uptake of the glucose analog 2-NBDG. Cells had limited glycolytic capacity both at steady state and after blockade of mitochondrial ATP synthesis, which was associated with diminished hexokinase 2 expression. Finally, the maximal respiration capacity of activated IRF4 −/− CD4 + T cells was reduced. Thus, metabolic performance of activated IRF4 −/− CD4 + T cells was profoundly restricted and this limitation was likely responsible for the impaired response of IRF4 −/− CD4 + T cells. Our data for IRF4 −/− T H1 cells resemble results for IRF4 −/− CD8 + T cells. These cells become activated but cannot sustain proliferation and effector function which eventually results in the collapse of the response. A similar scenario might occur during T H1 responses. IRF4
−/− CD4 + T cells become activated but fail to express genes required for proliferation and effector functions at adequate levels to allow effective T H1 differentiation and to sustain the response. We propose that this scenario is not restricted to T H1 differentiation but is also relevant for the deficiency of IRF4 −/− CD4 + T cells to differentiate into other T H cell subsets. Thus, IRF4 is a fundamental transcription factor for all conventional T cells that controls adaptation of gene expression to the requirements of effector cells.
Material and Methods
Mice and infection. IRF4
−/− mice 8 , RAG1 −/− mice 41 , OT-II mice 42 and CD90.1 congenic C57BL/6 mice (B6.PL-Thy1a/CyJ; Jackson, Bar Harbor, ME) were bred under specific pathogen-free conditions in the animal facility of the University Medical Center Hamburg-Eppendorf. Experiments were performed according to guidelines of the Deutsches Tierschutzgesetz and approved by the local committee for animal experiments of the City of Hamburg (permit number: 81/14). Mice were infected i.v. or i.p. with the indicated doses of either wild type Listeria monocytogenes (Lm) or of a L. monocytogenes strain recombinant for ovalbumin (LmOVA) 11, 37 . Bacterial inocula were controlled by plating serial dilutions on tryptic soy broth (TSB) agar plates.
Cell isolation and cell culture. Cells from spleens were obtained by mashing the disintegrated organs through cell sieves into PBS followed by erythrocyte lysis with ACK lysing buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , 100 μ M EDTA, pH ~7.2). For induction of cytokine production, cells were incubated at 1-5 × 10 6 cells/ml in culture medium (RPMI 1640 medium supplemented with 5% fetal calf serum, glutamine, inhibitors were determined as described in the material method section. (d) Competitive transfer of WT and IRF4 −/− OT-II T cells was done as described in Fig. 4 . Four days after transfer, OT-II cells from spleen were analyzed for size (FSC-A) and CD71 expression. Spleen cells were also in incubated with 30 μ M 2-NBDG in glucose-free medium and after 2 h, 2-NBDG uptake was measured. pyruvate, 2-mercaptoethanol and gentamicin) and stimulated for 4 h with 10 −5 M ovalbumin peptide (OVA 323-339 ; ISQAVHAAHAEINEAGR) or 10 −5 M listeriolysin O peptide (LLO 189-201 ; WNEKYAQAYPNVS) (both JPT Peptide Technologies, Berlin, Germany), or with 50 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma Aldrich, St. Louis, MO) and 1 μ M ionomycin (Sigma Aldrich). 10 μ g/ml brefeldin A (Sigma Aldrich) was added for the last 3.5 h of culture to prevent cytokine secretion. Subsequently cells were analyzed by flow cytometry 38, 43 . For in vitro T H1 cell differentiation, CD4 + T cells were purified using Mouse CD4 + T Cell Isolation Kit (Easy Sep, Stemcell Technologies, Vancouver, Canada). Cells were incubated for up to 7 days in 24-well plates coated with anti-CD3 (clone 145 2C11, Biolegend, San Diego, CA). Cultures were supplemented with 2 μ g/ml anti-CD28 (37.51), 20 U/ml rhIL-2 (Novartis, Basel, Switzerland), and 10 ng/ml IL-12 (Biolegend). The medium was replaced depending on the pH-indicator. In some experiments, 2 μ g/ml anti-IL-4 (11B11) was added to prevent cells from T H2 differentiation. In competitive cultures, CD4 + T cells from congenic CD90.1 + WT mice and CD90.2 + IRF4
−/− mice were mixed at a ratio of 1:1 and stimulated as described. For analysis of glucose uptake, CD4 + T cells from cell culture or directly isolated from infected mice were incubated for 2 h in glucose free RPMI 1640 medium (Life Technologies, Carlsbad, CA) with 30 μ M 2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose; Life Technologies). Cells were washed, stained for surface markers and analyzed by flow cytometry. Proliferation was measured by loss of CFSE staining intensity and apoptosis was determined by FLICA and propidium iodide staining as described 11 . mRNA expression was determined by RT-PCR as described previously 44 . Primer sequences are available upon request. All samples were run in triplicates. Results were normalized to the expression of 18S rRNA and are presented as relative expression, which was calculated as 2 −Δct × 1000. 
Extracellular flux assays. CD4
+ T cells were purified from spleens of WT and IRF4 −/− mice and incubated for 18 h with the T cell expansion and activation kit based on anti-CD3 and anti-CD28 stimulation according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). 4.5 × 10 5 cells/well were transferred to analysis plates (Seahorse Bioscience, North Billerica, MA) coated with CellTak (Corning, Corning, NY, USA) and plates were centrifuged to accumulate cells at the bottom of the plates. For determination of oxygen consumption rates (OCR), cells were washed and incubated in XF assay medium, 1 mM sodium pyruvate and 25 mM glucose (Seahorse Bioscience). Cells were analyzed using a XF-24 Extracellular Flux Analyzer (Seahorse Bioscience) according to the manufacturer's protocols. During OCR analysis, cells were treated with 1 μ M oligomycin, 0.9 μ M fluorocarbonyl cyanide phenylhydrazone (FCCP), 1 μ M rotenone and 1 μ M antimycin A (Seahorse Bioscience). For the analysis of extracellular acidification rates (ECAR), cells were pretreated as described above and incubated in analysis plates in glucose-and pyruvate-free DMEM 5030 (Sigma Aldrich). Cells were treated with 10 mM glucose, 1 μ M oligomycin and 100 mM 2-DG (2-deoxyglucose, Seahorse Bioscience) during the assay. OCR and ECAR values were calculated using the program provided by the manufacturer.
Statistical analysis.
Statistical analyses were performed with Prism software (GraphPad Software Inc., La Jolla, CA, USA). Results were analyzed with the unpaired t test or in case of competitive cultures or transfers with a paired t test. A p-value of <0.05 was considered significant (*p < 0.05; **p < 0.01; ***p < 0.001; ns: not significant).
